Click here to learn more about the underlying causes of PAH and our lead clinical product candidate, seralutinib »
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
Phase 2 ongoing
Phase 1 ongoing
*Targets to be disclosed